Table 1 Patients’ characteristics with PDAC used for xenografting
From: Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine
Xenograft no. | Sex | Age (y) | pG | pT | pN | pM | pR | PNI | VI | LVI | Preop RCT | Postop RCT/CT | OS (m) | DFS (m) | SP% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
101* | F | 45.5 | 2 | 4 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | RCT | 35.4 | 18.5 | 1.5 |
110* | M | 77.8 | 2 | 3 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1.1 | 1.1 | 6.0 |
112* | F | 77.8 | 2 | 3 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | CT | 10.1 | 3.6 | 6.8 |
127 | M | 52.9 | 2 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | CT | 37.7 | 34.8 | 6.4 |
128* | M | 53.6 | 2 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | CT | 11.2 | 10.2 | 6.8 |
136* | M | 78.4 | 2 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37.8 | 24.5 | 6.1 |
151° | M | 45.9 | 2 | 3 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | CT | 13.5 | 10.3 | 17.6 |
169 | F | 80.5 | 2 | 3 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 10.2 | 2.4 | 4.3 |
174**,° | M | 66.9 | 2 | 3 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | CT | 43.3 | 19.8 | 2.7 |
178** | F | 53.2 | 3 | 4 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | CT | 27.2 | 27.2 | 12.0 |
199 | M | 52.2 | 3 | 3 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | CT | 23.5 | 4.9 | 5.0 |
207**,° | F | 67.0 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CT | 7.2 | 5.5 | 10.0 |
218 | F | 62.6 | 3 | 3 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0.3 | 0.3 | 1.4 |
223**,° | F | 57.3 | 2 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 24.5 | 7.4 | 2.0 |
229** | F | 73.2 | 3 | 3 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 4.5 | 4.0 | 5.4 |
235**,° | F | 57.4 | 1 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | CT | 19.6 | 7.7 | 2.1 |
241**,° | F | 74.6 | 2 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 6.9 | 2.9 | 2.7 |